XML 129 R111.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidating Financial Statements (Condensed Consolidating Statement of Cash Flows) (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2015
Operating Activities                      
Net income (loss) $ 11,090 $ 31,641 $ 32,195 $ (5,531) $ 13,936 $ 27,995 $ 31,803 $ 26,173 $ 69,395 $ 99,907 $ 78,260
Adjustments to reconcile net income (loss) to net cash provided by operating activities:                      
Depreciation and amortization                 25,792 23,676 17,740
Loss on divestitures and sales of property and equipment 268 $ (3,405) $ (496) 55,453         51,820 0 0
Gain on sale of asset                 0 0 (1,133)
Deferred income taxes                 (5,778) 46,152 28,922
Long term income taxes payable                 581 (332) 2,294
Amortization of debt origination costs                 8,633 8,994 8,821
Stock-based compensation costs                 8,148 9,954 6,918
Loss on extinguishment of debt                 1,420 17,970 0
Lease termination costs                 524 0 785
Premium payment on 2012 Senior Notes                 0 (10,158) 0
Loss (gain) on sale or disposal of property and equipment                 573 (35) 321
Equity in (income) loss of subsidiaries                 0 0 0
Changes in operating assets and liabilities, net of effects from acquisitions:                      
Accounts receivable                 (18,938) 1,824 1,608
Inventories                 (10,262) (3,005) 15,360
Prepaid expenses and other assets                 (1,996) (7,921) 4,664
Accounts payable                 21,447 (11,348) (17,637)
Accrued liabilities                 2,497 (1,328) 9,332
Noncurrent assets and liabilities                 (6,084) 0 0
Net cash provided by operating activities                 147,772 174,350 156,255
Investing Activities                      
Purchases of property and equipment                 (2,977) (3,568) (6,101)
Proceeds from divestitures                 110,717 0 18,500
Proceeds from the sale of property and equipment                 85 344 0
Proceeds from sale of asset                 0 0 10,000
Proceeds from Insight Pharmaceuticals working capital arbitration settlement                 0 7,237 0
Proceeds from DenTek working capital arbitration settlement                 1,419 0 0
Acquisition of DenTek, less cash acquired                 0 (226,984) 0
Acquisition of Insight Pharmaceuticals, less cash acquired                 0 0 (749,666)
Acquisition of the Hydralyte brand                 0 0 (77,991)
Acquisition of C.B. Fleet, less cash acquired                 (803,839) 0 0
Intercompany activity, net                 0 0 0
Net cash used in investing activities                 (694,595) (222,971) (805,258)
Financing Activities                      
Proceeds from issuance of Term Loan                 1,427,000 0 720,000
Term Loan repayments resulting from refinancing                 (687,000) 0 0
Proceeds from issuance of 2016 Senior Notes                 0 350,000 0
Repayment of 2012 Senior Notes                 0 (250,000) 0
Borrowings under Bridge term loans                 0 80,000 0
Repayments under Bridge term loans                 0 (80,000) 0
Term Loan repayments                 (175,500) (60,000) (130,000)
Borrowings under revolving credit agreement                 110,000 115,000 124,600
Repayments under revolving credit agreement                 (105,000) (96,100) (58,500)
Payments of debt origination costs                 (11,140) (11,828) (16,072)
Proceeds from exercise of stock options                 4,028 6,689 3,954
Proceeds from restricted stock exercises                 0 544 57
Excess tax benefits from share-based awards                 900 1,960 1,330
Fair value of shares surrendered as payment of tax withholding                 (1,431) (2,229) (2,104)
Intercompany activity, net                 0 0 0
Net cash provided by financing activities                 561,857 54,036 643,265
Effects of exchange rate changes on cash and cash equivalents                 (409) 497 (1,275)
Increase (decrease) in cash and cash equivalents                 14,625 5,912 (7,013)
Cash and cash equivalents - beginning of year       27,230       21,318 27,230 21,318 28,331
Cash and cash equivalents - end of year 41,855       27,230       41,855 27,230 21,318
Prestige Brands Holdings, Inc.                      
Operating Activities                      
Net income (loss)                 69,395 99,907 78,260
Adjustments to reconcile net income (loss) to net cash provided by operating activities:                      
Depreciation and amortization                 3,170 4,050 3,381
Loss on divestitures and sales of property and equipment                 0    
Gain on sale of asset                     0
Deferred income taxes                 316 136 (192)
Long term income taxes payable                 0 0 0
Amortization of debt origination costs                 0 0 0
Stock-based compensation costs                 8,148 9,794 6,918
Loss on extinguishment of debt                 0 0  
Lease termination costs                 0   0
Premium payment on 2012 Senior Notes                   0  
Loss (gain) on sale or disposal of property and equipment                 0 0 0
Equity in (income) loss of subsidiaries                 (67,467) (98,803) (76,383)
Changes in operating assets and liabilities, net of effects from acquisitions:                      
Accounts receivable                 0 0 473
Inventories                 0 0 0
Prepaid expenses and other assets                 (2,261) (9,580) 2,273
Accounts payable                 (790) 929 (2,457)
Accrued liabilities                 620 1,907 2,650
Net cash provided by operating activities                 11,131 8,340 14,923
Investing Activities                      
Purchases of property and equipment                 (1,153) (2,460) (5,029)
Proceeds from divestitures                 0   0
Proceeds from the sale of property and equipment                 0 0  
Proceeds from sale of asset                     0
Proceeds from Insight Pharmaceuticals working capital arbitration settlement                   0  
Proceeds from DenTek working capital arbitration settlement                 0    
Acquisition of DenTek, less cash acquired                   0  
Acquisition of Insight Pharmaceuticals, less cash acquired                     0
Acquisition of the Hydralyte brand                     0
Intercompany activity, net                 0 0 0
Net cash used in investing activities                 (1,153) (2,460) (5,029)
Financing Activities                      
Proceeds from issuance of Term Loan                 0   0
Term Loan repayments resulting from refinancing                 0    
Proceeds from issuance of 2016 Senior Notes                   0  
Repayment of 2012 Senior Notes                   0  
Borrowings under Bridge term loans                   0  
Repayments under Bridge term loans                   0  
Term Loan repayments                 0 0 0
Borrowings under revolving credit agreement                 0 0 0
Repayments under revolving credit agreement                 0 0 0
Payments of debt origination costs                 0 0 0
Proceeds from exercise of stock options                 4,028 6,689 3,954
Proceeds from restricted stock exercises                   544 57
Excess tax benefits from share-based awards                 900 1,960 1,330
Fair value of shares surrendered as payment of tax withholding                 (1,431) (2,229) (2,104)
Intercompany activity, net                 (11,747) (19,791) (26,388)
Net cash provided by financing activities                 (8,250) (12,827) (23,151)
Effects of exchange rate changes on cash and cash equivalents                 0 0 0
Increase (decrease) in cash and cash equivalents                 1,728 (6,947) (13,257)
Cash and cash equivalents - beginning of year       4,440       11,387 4,440 11,387 24,644
Cash and cash equivalents - end of year 6,168       4,440       6,168 4,440 11,387
Prestige Brands, Inc., the issuer                      
Operating Activities                      
Net income (loss)                 68,463 90,201 77,881
Adjustments to reconcile net income (loss) to net cash provided by operating activities:                      
Depreciation and amortization                 634 594 592
Loss on divestitures and sales of property and equipment                 0    
Gain on sale of asset                     0
Deferred income taxes                 (3,691) 1,272 2,462
Long term income taxes payable                 0 0 0
Amortization of debt origination costs                 8,633 8,994 8,821
Stock-based compensation costs                 0 0 0
Loss on extinguishment of debt                 1,420 17,970  
Lease termination costs                 0   0
Premium payment on 2012 Senior Notes                   (10,158)  
Loss (gain) on sale or disposal of property and equipment                 0 0 0
Equity in (income) loss of subsidiaries                 (49,302) (70,953) (51,573)
Changes in operating assets and liabilities, net of effects from acquisitions:                      
Accounts receivable                 (3,762) 2,514 (294)
Inventories                 (7,073) (744) 5,690
Prepaid expenses and other assets                 (1,428) (116) (28)
Accounts payable                 6,933 814 (829)
Accrued liabilities                 184 (2,749) 1,384
Net cash provided by operating activities                 21,011 37,639 44,106
Investing Activities                      
Purchases of property and equipment                 (327) (93) (119)
Proceeds from divestitures                 0   0
Proceeds from the sale of property and equipment                 0 0  
Proceeds from sale of asset                     0
Proceeds from Insight Pharmaceuticals working capital arbitration settlement                   0  
Proceeds from DenTek working capital arbitration settlement                 0    
Acquisition of DenTek, less cash acquired                   0  
Acquisition of Insight Pharmaceuticals, less cash acquired                     0
Acquisition of the Hydralyte brand                     0
Intercompany activity, net                 (823,723) (228,343) (809,157)
Net cash used in investing activities                 (824,050) (228,436) (809,276)
Financing Activities                      
Proceeds from issuance of Term Loan                 1,427,000   720,000
Term Loan repayments resulting from refinancing                 (687,000)    
Proceeds from issuance of 2016 Senior Notes                   350,000  
Repayment of 2012 Senior Notes                   (250,000)  
Borrowings under Bridge term loans                   80,000  
Repayments under Bridge term loans                   (80,000)  
Term Loan repayments                 (175,500) (60,000) (130,000)
Borrowings under revolving credit agreement                 110,000 115,000 124,600
Repayments under revolving credit agreement                 (105,000) (96,100) (58,500)
Payments of debt origination costs                 (11,140) (11,828) (16,072)
Proceeds from exercise of stock options                 0 0 0
Proceeds from restricted stock exercises                   0 0
Excess tax benefits from share-based awards                 0 0 0
Fair value of shares surrendered as payment of tax withholding                 0 0 0
Intercompany activity, net                 244,679 143,725 125,142
Net cash provided by financing activities                 803,039 190,797 765,170
Effects of exchange rate changes on cash and cash equivalents                 0 0 0
Increase (decrease) in cash and cash equivalents                 0 0 0
Cash and cash equivalents - beginning of year       0       0 0 0 0
Cash and cash equivalents - end of year 0       0       0 0 0
Combined Subsidiary Guarantors                      
Operating Activities                      
Net income (loss)                 48,737 78,941 50,209
Adjustments to reconcile net income (loss) to net cash provided by operating activities:                      
Depreciation and amortization                 21,454 18,617 12,752
Loss on divestitures and sales of property and equipment                 51,820    
Gain on sale of asset                     (1,133)
Deferred income taxes                 (1,934) 45,070 26,795
Long term income taxes payable                 581 (332) 2,294
Amortization of debt origination costs                 0 0 0
Stock-based compensation costs                 0 0 0
Loss on extinguishment of debt                 0 0  
Lease termination costs                 524   785
Premium payment on 2012 Senior Notes                   0  
Loss (gain) on sale or disposal of property and equipment                 573 1 0
Equity in (income) loss of subsidiaries                 (9,481) (8,564) (2,013)
Changes in operating assets and liabilities, net of effects from acquisitions:                      
Accounts receivable                 (5,725) (388) 5,146
Inventories                 (2,856) 213 8,981
Prepaid expenses and other assets                 1,235 1,977 2,631
Accounts payable                 14,155 (11,284) (16,734)
Accrued liabilities                 1,798 (1,943) 3,560
Noncurrent assets and liabilities                 (6,084)    
Net cash provided by operating activities                 114,797 122,308 93,273
Investing Activities                      
Purchases of property and equipment                 (1,378) (521) (739)
Proceeds from divestitures                 110,717   18,500
Proceeds from the sale of property and equipment                 85 0  
Proceeds from sale of asset                     10,000
Proceeds from Insight Pharmaceuticals working capital arbitration settlement                   7,237  
Proceeds from DenTek working capital arbitration settlement                 1,419    
Acquisition of DenTek, less cash acquired                   (226,984)  
Acquisition of Insight Pharmaceuticals, less cash acquired                     (749,666)
Acquisition of the Hydralyte brand                     0
Acquisition of C.B. Fleet, less cash acquired                 (803,839)    
Intercompany activity, net                 823,723 228,343 731,166
Net cash used in investing activities                 130,727 8,075 9,261
Financing Activities                      
Proceeds from issuance of Term Loan                 0   0
Term Loan repayments resulting from refinancing                 0    
Proceeds from issuance of 2016 Senior Notes                   0  
Repayment of 2012 Senior Notes                   0  
Borrowings under Bridge term loans                   0  
Repayments under Bridge term loans                   0  
Term Loan repayments                 0 0 0
Borrowings under revolving credit agreement                 0 0 0
Repayments under revolving credit agreement                 0 0 0
Payments of debt origination costs                 0 0 0
Proceeds from exercise of stock options                 0 0 0
Proceeds from restricted stock exercises                   0 0
Excess tax benefits from share-based awards                 0 0 0
Fair value of shares surrendered as payment of tax withholding                 0 0 0
Intercompany activity, net                 (243,439) (127,484) (102,534)
Net cash provided by financing activities                 (243,439) (127,484) (102,534)
Effects of exchange rate changes on cash and cash equivalents                 0 0 0
Increase (decrease) in cash and cash equivalents                 2,085 2,899 0
Cash and cash equivalents - beginning of year       2,899       0 2,899 0 0
Cash and cash equivalents - end of year 4,984       2,899       4,984 2,899 0
Combined Non-Guarantor Subsidiaries                      
Operating Activities                      
Net income (loss)                 9,481 8,564 2,013
Adjustments to reconcile net income (loss) to net cash provided by operating activities:                      
Depreciation and amortization                 534 415 1,015
Loss on divestitures and sales of property and equipment                 0    
Gain on sale of asset                     0
Deferred income taxes                 (469) (326) (143)
Long term income taxes payable                 0 0 0
Amortization of debt origination costs                 0 0 0
Stock-based compensation costs                 160 0
Loss on extinguishment of debt                 0 0  
Lease termination costs                 0   0
Premium payment on 2012 Senior Notes                   0  
Loss (gain) on sale or disposal of property and equipment                 0 (36) 321
Equity in (income) loss of subsidiaries                 0 0 0
Changes in operating assets and liabilities, net of effects from acquisitions:                      
Accounts receivable                 (9,451) (302) (3,717)
Inventories                 (764) (1,860) 555
Prepaid expenses and other assets                 458 (202) (212)
Accounts payable                 1,149 (1,807) 2,383
Accrued liabilities                 (105) 1,457 1,738
Net cash provided by operating activities                 833 6,063 3,953
Investing Activities                      
Purchases of property and equipment                 (119) (494) (214)
Proceeds from divestitures                 0   0
Proceeds from the sale of property and equipment                 344  
Proceeds from sale of asset                     0
Proceeds from Insight Pharmaceuticals working capital arbitration settlement                   0  
Proceeds from DenTek working capital arbitration settlement                 0    
Acquisition of DenTek, less cash acquired                   0  
Acquisition of Insight Pharmaceuticals, less cash acquired                     0
Acquisition of the Hydralyte brand                     (77,991)
Intercompany activity, net                 0 0 77,991
Net cash used in investing activities                 (119) (150) (214)
Financing Activities                      
Proceeds from issuance of Term Loan                 0   0
Term Loan repayments resulting from refinancing                 0    
Proceeds from issuance of 2016 Senior Notes                   0  
Repayment of 2012 Senior Notes                   0  
Borrowings under Bridge term loans                   0  
Repayments under Bridge term loans                   0  
Term Loan repayments                 0 0 0
Borrowings under revolving credit agreement                 0 0 0
Repayments under revolving credit agreement                 0 0 0
Payments of debt origination costs                 0 0 0
Proceeds from exercise of stock options                 0 0 0
Proceeds from restricted stock exercises                   0 0
Excess tax benefits from share-based awards                 0 0 0
Fair value of shares surrendered as payment of tax withholding                 0 0 0
Intercompany activity, net                 10,507 3,550 3,780
Net cash provided by financing activities                 10,507 3,550 3,780
Effects of exchange rate changes on cash and cash equivalents                 (409) 497 (1,275)
Increase (decrease) in cash and cash equivalents                 10,812 9,960 6,244
Cash and cash equivalents - beginning of year       19,891       9,931 19,891 9,931 3,687
Cash and cash equivalents - end of year 30,703       19,891       30,703 19,891 9,931
Eliminations                      
Operating Activities                      
Net income (loss)                 (126,681) (177,706) (130,103)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:                      
Depreciation and amortization                 0 0 0
Loss on divestitures and sales of property and equipment                 0    
Gain on sale of asset                     0
Deferred income taxes                 0 0 0
Long term income taxes payable                 0 0 0
Amortization of debt origination costs                 0 0 0
Stock-based compensation costs                 0 0 0
Loss on extinguishment of debt                 0 0  
Lease termination costs                 0   0
Premium payment on 2012 Senior Notes                   0  
Loss (gain) on sale or disposal of property and equipment                 0 0 0
Equity in (income) loss of subsidiaries                 126,250 178,320 129,969
Changes in operating assets and liabilities, net of effects from acquisitions:                      
Accounts receivable                 0 0 0
Inventories                 431 (614) 134
Prepaid expenses and other assets                 0 0 0
Accounts payable                 0 0 0
Accrued liabilities                 0 0 0
Net cash provided by operating activities                 0 0 0
Investing Activities                      
Purchases of property and equipment                 0 0 0
Proceeds from divestitures                 0   0
Proceeds from the sale of property and equipment                 0 0  
Proceeds from sale of asset                     0
Proceeds from Insight Pharmaceuticals working capital arbitration settlement                   0  
Proceeds from DenTek working capital arbitration settlement                 0    
Acquisition of DenTek, less cash acquired                   0  
Acquisition of Insight Pharmaceuticals, less cash acquired                     0
Acquisition of the Hydralyte brand                     0
Intercompany activity, net                 0 0 0
Net cash used in investing activities                 0 0 0
Financing Activities                      
Proceeds from issuance of Term Loan                 0   0
Term Loan repayments resulting from refinancing                 0    
Proceeds from issuance of 2016 Senior Notes                   0  
Repayment of 2012 Senior Notes                   0  
Borrowings under Bridge term loans                   0  
Repayments under Bridge term loans                   0  
Term Loan repayments                 0 0 0
Borrowings under revolving credit agreement                 0 0 0
Repayments under revolving credit agreement                 0 0 0
Payments of debt origination costs                 0 0 0
Proceeds from exercise of stock options                 0 0 0
Proceeds from restricted stock exercises                   0 0
Excess tax benefits from share-based awards                 0 0 0
Fair value of shares surrendered as payment of tax withholding                 0 0 0
Intercompany activity, net                 0 0 0
Net cash provided by financing activities                 0 0 0
Effects of exchange rate changes on cash and cash equivalents                 0 0 0
Increase (decrease) in cash and cash equivalents                 0 0 0
Cash and cash equivalents - beginning of year       $ 0       $ 0 0 0 0
Cash and cash equivalents - end of year $ 0       $ 0       $ 0 $ 0 $ 0